HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Halozyme Therapeutics (HALO) Tops Q1 EPS by 10c, Beats on Revenue; Offers Guidance
May 7, 2024 4:05 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196 million versus the consensus estimate of $199.74 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90. Halozyme Therapeutics sees FY2024... More
